XML 100 R119.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative and Other Relationships (Details Textual) | 3 Months Ended | 12 Months Ended |  | 12 Months Ended | 1 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended |  | 3 Months Ended |  | 1 Months Ended | 3 Months Ended |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  | 12 Months Ended | 1 Months Ended | 12 Months Ended |  | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 USD ($) | Sep. 30, 2013 USD ($) | Jun. 30, 2013 USD ($) | Mar. 31, 2013 USD ($) | Dec. 31, 2012 USD ($) | Sep. 30, 2012 USD ($) | Jun. 30, 2012 USD ($) | Mar. 31, 2012 USD ($) | Dec. 31, 2013 USD ($) | Dec. 31, 2012 USD ($) | Dec. 31, 2011 USD ($) | Jan. 31, 2007 Biogen Idec Hemophilia | Dec. 31, 2013 U.S USD ($) | Dec. 31, 2012 U.S USD ($) | Dec. 31, 2011 U.S USD ($) | Dec. 31, 2013 Maximum | Dec. 31, 2013 Minimum | Dec. 31, 2013 Roche Group - Genentech U.S USD ($) | Dec. 31, 2012 Roche Group - Genentech U.S USD ($) | Dec. 31, 2011 Roche Group - Genentech U.S USD ($) | Jun. 30, 2012 Genentech USD ($) | Dec. 31, 2013 Genentech USD ($) | Dec. 31, 2013 Elan USD ($) | Dec. 31, 2012 Elan USD ($) | Dec. 31, 2011 Elan USD ($) | Sep. 30, 2011 Acorda USD ($) | Dec. 31, 2013 Acorda USD ($) | Dec. 31, 2013 Swedish Orphan Biovitrum USD ($) | Dec. 31, 2013 Swedish Orphan Biovitrum Maximum USD ($) | Dec. 31, 2013 Swedish Orphan Biovitrum Minimum USD ($) | Dec. 31, 2013 AbbVie USD ($) | Dec. 31, 2011 Portola Pharmaceuticals USD ($) | Dec. 31, 2013 Portola Pharmaceuticals USD ($) | Dec. 31, 2012 ISIS Pharmaceuticals USD ($) | Jun. 30, 2012 ISIS Pharmaceuticals USD ($) | Jan. 31, 2012 ISIS Pharmaceuticals USD ($) | Dec. 31, 2013 ISIS Pharmaceuticals USD ($) | Sep. 30, 2013 ISIS Pharmaceuticals USD ($) | Dec. 31, 2012 ISIS Pharmaceuticals USD ($) | Jun. 30, 2012 ISIS Pharmaceuticals USD ($) | Mar. 31, 2012 ISIS Pharmaceuticals USD ($) | Jan. 31, 2014 ISIS Pharmaceuticals USD ($) | Jan. 31, 2014 Proteostasis Therapeutics USD ($) | Dec. 31, 2013 Proteostasis Therapeutics USD ($) | Dec. 31, 2013 Other research and discovery USD ($) | Dec. 31, 2013 RITUXAN USD ($) | Dec. 31, 2012 RITUXAN | Dec. 31, 2011 RITUXAN | Dec. 31, 2013 RITUXAN Maximum | Dec. 31, 2013 RITUXAN Minimum | Dec. 31, 2013 GAZYVA [Member] USD ($) | Dec. 31, 2013 Ocrelizumab Maximum | Dec. 31, 2013 Ocrelizumab Minimum | Feb. 29, 2012 Samsung Biosimilar Agreement USD ($) | Feb. 29, 2012 Samsung Biosimilar Agreement KRW | Dec. 31, 2013 Samsung Biosimilar Agreement USD ($) | Dec. 31, 2013 Samsung Biosimilar Agreement KRW | Dec. 31, 2012 Samsung Biosimilar Agreement USD ($) | Dec. 31, 2012 Samsung Biosimilar Agreement KRW | Dec. 31, 2013 New Anti-CD20 Third Party Anti CD-20 Roche Group - Genentech USD ($) | Dec. 31, 2012 New Anti-CD20 Third Party Anti CD-20 Roche Group - Genentech USD ($) | Dec. 31, 2011 New Anti-CD20 Third Party Anti CD-20 Roche Group - Genentech USD ($) | Mar. 31, 2013 Hoechst USD ($) | Mar. 31, 2013 Hoechst EUR (€) | Dec. 31, 2013 Hoechst USD ($) | Jun. 30, 2011 Hoechst RITUXAN Genentech USD ($) | Dec. 31, 2013 Cash and cash equivalents Samsung Biosimilar Agreement USD ($) | Dec. 31, 2013 Accrued Liabilities Samsung Biosimilar Agreement USD ($) | Dec. 31, 2011 Strategic Investments USD ($) | Dec. 31, 2013 Strategic Investments Portola Pharmaceuticals USD ($)
Collaborative arrangements and non-collaborative arrangement transactions |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalties Terms Of Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10% and 12% on sales of RITUXAN outside the U.S. and Canada, with the royalty period lasting 11 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty Period For Substantially All Remaining Royalty Bearing Sales Rest Of World |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | expire through 2012 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35.00% |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative and Other Relationships (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties as per collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12.00% | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of future development and commercialization expenses payable related to GAZYVA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future royalties percentage to be received on sale of ocrelizumab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 24.00% | 13.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of Co promotion Operating Profits first fifty million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Limit of gross sale of GAZYVA to be achieved in any 12 months under option one |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales Trigger Gross Sales Threshold |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future percentage of co-promotion operating profits |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 38.00% | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage Of Co Promotion Operating Losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimates of compensatory damages and interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 125,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Decrease In Share Of Co Promotion Profits Due To Estimated Compensation Damages |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 41,500,000 |  | 49,700,000 | 50,000,000 |  |  |  |
Compensatory damages and interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 108,000,000 |  |  |  |  |  |
Prejudgment interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 54,000,000 |  |  |  |  |  |
Revenue on sales in the rest of world for RITUXAN | 1,607,100,000 | [1],[2] | 1,453,600,000 | 1,385,900,000 | [3] | 1,095,800,000 | [4] | 1,074,700,000 | [5] | 1,039,100,000 | 1,076,800,000 | [6] | 975,400,000 | 5,542,331,000 | 4,166,074,000 | 3,836,117,000 |  | 3,581,000,000 | 2,176,800,000 | 1,954,800,000 |  |  |  |  |  |  | 41,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biogen Idec's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,085,200,000 | 1,031,700,000 | 872,700,000 |  | 8,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of share of Co promotion profits exceeding $50 million |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40.00% | 40.00% | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 130,000,000 | 120,000,000 |  | 36,800,000 |  |  |  |  | 10,000,000 | 75,000,000 | 30,000,000 | 12,000,000 | 29,000,000 |  |  | 2,500,000 | 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,700,000 | 35,400,000 | 26,900,000 |  |  |  |  | 21,000,000 | 15,000,000 |  |
Reimbursements of research and developments expense from Elan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,700,000 | 43,700,000 | 47,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursements of selling general and administrative expenses from Elan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,600,000 | 99,900,000 | 77,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount reflected in collaboration profit sharing line for collaboration |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 85,400,000 | 317,900,000 | 317,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected additional milestone payments for successful achievement of regulatory and commercial sales milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 375,000,000 |  |  |  |  |  | 406,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected additional milestone payments when certain sales threshold is met |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign sales required to trigger milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock acquired in acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration per product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of reimbursement expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development reimbursement expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement cost achieving period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Time period for paying remaining balance due |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term for revocation option right |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of development and commercial milestones. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount paid to purchase Portola equity |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,200,000 |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Loss From Sale Of Strategic Equity Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,500,000 | 7,100,000
Term of collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total upfront and milestone payments made to collaborative partner |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Prepaid research and discovery services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License Fee |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70,000,000 | 70,000,000 | 75,000,000 |  | 70,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected License Fee And Regulatory Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 130,000,000 | 130,000,000 | 150,000,000 |  | 130,000,000 | 130,000,000 | 130,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments for product candidate using a different modality |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Milestone Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000 | 59,000,000 |  |  |  | 10,000,000 | 59,000,000 |  | 40,000,000 |  | 197,500,000 |  |  |  |  |  |  |  |  |  |  |  | 85,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments By Third Party In Joint Venture As Per Agreement. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000,000 | 280,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other Assets, Noncurrent | 594,350,000 |  |  |  |  |  |  | 274,054,000 |  |  |  |  |  | 594,350,000 | 274,054,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint Venture Owner Ship Percentage By Third Party. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 85.00% | 85.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 45,000,000 | 49,500,000,000 | 23,900,000 | 25,200,000,000 | 27,800,000 | 29,700,000,000 |  |  |  |  |  |  |  |  |  |  |
Percentage of equity interest to the portion of total capital stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15.00% | 15.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment Ownership Percentage Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.90% | 49.90% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,400,000 | 13,500,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Income (Loss) from Equity Method Investments |  |  |  |  |  |  |  |  |  |  |  |  |  | (17,224,000) | (4,518,000) | 0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (17,200,000) |  | (4,500,000) |  |  |  |  |  |  |  |  |  |  |  |
Other revenues from external customers | $ 89,400,000 | [1],[2] | $ 71,000,000 | $ 48,800,000 | [3] | $ 54,700,000 | [4] | $ 62,300,000 | [5] | $ 58,600,000 | $ 59,600,000 | [6] | $ 32,000,000 | $ 263,851,000 | $ 212,464,000 | $ 215,920,000 |  | $ 193,500,000 | $ 170,200,000 | $ 187,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 43,100,000 |  | $ 13,300,000 |  |  |  |  |  |  |  |  |  |  |  |
[1] | Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[2] | Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[3] | Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[4] | Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
[5] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
[6] | Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Additional milestone payments for product candidate using a different modality + References No definition available. + Details
Name: | biib_Additionalmilestonepaymentsforproductcandidateusingadifferentmodality
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount paid to purchase Portola equity. + References No definition available. + Details
Name: | biib_AmountPaidToPurchaseOfEquityOfCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount reflected in collaboration profit sharing line for collaboration. + References No definition available. + Details
Name: | biib_AmountReflectedInCollaborationProfitSharingLineForCollaboration
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | biib_CollaborationsTextualAbstract
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Consideration per product developed. + References No definition available. + Details
Name: | biib_ConsiderationPerProductDeveloped
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment. + References No definition available. + Details
Name: | biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Decrease in share of co-promotion profits due to estimated compensation damages. + References No definition available. + Details
Name: | biib_DecreaseInShareOfCoPromotionProfitsDueToEstimatedCompensationDamages
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity method investment ownership percentage maximum. + References No definition available. + Details
Name: | biib_EquityMethodInvestmentOwnershipPercentageMaximum
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Estimated additional payments upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Estimates of compensatory damages and interest. + References No definition available. + Details
Name: | biib_EstimatesOfCompensatoryDamagesAndInterest
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected additional milestone payments on successful achievement of regulatory and commercial sales milestones. + References No definition available. + Details
Name: | biib_ExpectedAdditionalMilestonePaymentsOnSuccessfulAchievementOfRegulatoryAndCommercialSalesMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Expected additional milestone payments when meeting certain sales threshold. + References No definition available. + Details
Name: | biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Expected license fee and regulatory milestone payments. + References No definition available. + Details
Name: | biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Foreign sales required to trigger milestone. + References No definition available. + Details
Name: | biib_ForeignSalesRequiredToTriggerMilestone
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future percentage of co-promotion operating profits + References No definition available. + Details
Name: | biib_Futurepercentageofcopromotionoperatingprofits
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future royalties percentage to be received on sale of product. + References No definition available. + Details
Name: | biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain (loss) from sale of strategic equity investments. + References No definition available. + Details
Name: | biib_GainLossFromSaleOfStrategicEquityInvestments
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Investments by third party in joint venture as per agreement + References No definition available. + Details
Name: | biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Joint venture owner ship percentage by third party. + References No definition available. + Details
Name: | biib_JointVentureOwnerShipPercentageByThirdParty
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Fee + References No definition available. + Details
Name: | biib_LicenseFee
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestones payments made to collaborative partners. + References No definition available. + Details
Name: | biib_MilestonesPaymentsMadeToCollaborativePartners
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage Of Co Promotion Operating Losses + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingLosses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of co promotion operating profits first fifty million. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillion
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of co promotion operating profits greater than first fifty million option two sub option three. + References No definition available. + Details
Name: | biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of development and commercialization expenses payable related. + References No definition available. + Details
Name: | biib_PercentageOfDevelopmentAndCommercializationExpensesPayableRelated
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development reimbursement expenses. + References No definition available. + Details
Name: | biib_PercentageOfDevelopmentReimbursementExpenses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of reimbursement expenses. + References No definition available. + Details
Name: | biib_PercentageOfReimbursementExpenses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalties as per collaboration. + References No definition available. + Details
Name: | biib_PercentageOfRoyaltiesAsPerCollaboration
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for granting of approval by approving authority. + References No definition available. + Details
Name: | biib_PeriodForGrantingOfApprovalByApprovingAuthority
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of collaboration agreement. + References No definition available. + Details
Name: | biib_PeriodOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prejudgment interest + References No definition available. + Details
Name: | biib_PrejudgmentInterest
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursement cost achieving period. + References No definition available. + Details
Name: | biib_ReimbursementCostAchievingPeriod
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursements of research and developments expense from collaboration partner. + References No definition available. + Details
Name: | biib_ReimbursementsOfResearchAndDevelopmentsExpenseFromCollaborationPartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reimbursements of selling general and administrative expenses from collaboration partner. + References No definition available. + Details
Name: | biib_ReimbursementsOfSellingGeneralAndAdministrativeExpensesFromCollaborationPartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalties terms of collaboration agreement. + References No definition available. + Details
Name: | biib_RoyaltiesTermsOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty period for substantially all of the remaining royalty-bearing sales of RITUXAN in the rest of world. + References No definition available. + Details
Name: | biib_RoyaltyPeriodForSubstantiallyAllRemainingRoyaltyBearingSalesRestOfWorld
Namespace Prefix: | biib_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales trigger gross sales threshold. + References No definition available. + Details
Name: | biib_SalesTriggerGrossSalesThreshold
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of collaboration agreement + References No definition available. + Details
Name: | biib_Termofcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one. + References No definition available. + Details
Name: | biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Threshold of gross sales to be achieved in any twelve consecutive months under option one. + References No definition available. + Details
Name: | biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Time period for paying remaining balance due. + References No definition available. + Details
Name: | biib_TimePeriodForPayingRemainingBalanceDue
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total upfront and milestone payments made to collaborative partner. + References No definition available. + Details
Name: | biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=16385135&loc=d3e33749-111570 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.12) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 9 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349 + Details
Name: | us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 17 -Article 5 + Details
Name: | us-gaap_OtherAssetsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + References No definition available. + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration